ArticleEuropean journal of nuclear medicine and molecular imaging2026

Increased progression free survival with radiolabelled somatostatin receptor antagonist versus standard peptide receptor radionuclide therapy in patients with somatostatin receptor positive tumours.

Abdulrafee Mushaweh et al.PubMed ↗Publisher ↗

No numbers read from the abstract.